NEW YORK, Feb. 3 (Xinhua) -- U.S. drugmaker Pfizer on Tuesday reported fourth-quarter financial results that surpassed analyst expectations, even as demand for its pandemic-era products continued to wane.
The New York-based drugmaker reported fourth-quarter revenue of 17.6 billion U.S. dollars, representing a 3 percent operational decline year over year. Adjusted diluted earnings per share (EPS) for the quarter came in at 0.66 dollars.
